Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

BACKGROUND: Sunitinib represents a widely used therapy for metastatic renal cell carcinoma patients. Even so, there is a group of patients who show toxicity without clinical benefit. In this work, we have analysed pivotal molecular targets involved in angiogenesis (vascular endothelial growth factor...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: del Puerto-Nevado, L, Rojo, F, Zazo, S, Caramés, C, Rubio, G, Vega, R, Chamizo, C, Casado, V, Martínez-Useros, J, Rincón, R, Rodríguez-Remírez, M, Borrero-Palacios, A, Cristóbal, I, Madoz-Gúrpide, J, Aguilera, O, García-Foncillas, J
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2014
Materias:
Molecular Diagnostics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4037833/
https://ncbi.nlm.nih.gov/pubmed/24786599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.225
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares